NEW YORK – The Belgian Society of Medical Oncology (BSMO) on Thursday announced a study to evaluate the use of genomic profiling and precision oncology for patients with advanced cancer in Belgium.
BSMO will begin the study, dubbed BALLETT, next month. It will enroll 864 patients with advanced metastatic cancer. These patients will be offered comprehensive genomic profiling, and the deidentified data from the study will be added to a newly established national genomic tumor database overseen by Belgium’s Scientific Institute for Public Health, Sciensano.